Docoh
Loading...

LGND Ligand Pharmaceuticals

Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenx Inc., the company went public in 1992.

Company profile

Ticker
LGND, LGNXZ, LGNYZ, LGNZZ, LGNDZ
Exchange
Website
CEO
John Higgins
Employees
Incorporated
Location
Fiscal year end
Former names
LIGAND PHARMACEUTICALS
SEC CIK
IRS number
770160744

LGND stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

6 May 21
31 Jul 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 32.2M 32.2M 32.2M 32.2M 32.2M 32.2M
Cash burn (monthly) 5.26M 7.17M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 21.11M 28.81M n/a n/a n/a n/a
Cash remaining 11.08M 3.38M n/a n/a n/a n/a
Runway (months of cash) 2.1 0.5 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
12 Jul 21 Jennifer R. Cochran Common Stock Grant Aquire A No No 0 1,161 0 1,161
12 Jul 21 Jennifer R. Cochran NQSO Common Stock Grant Aquire A No No 126.36 4,508 569.63K 4,508
30 Jun 21 Higgins John L Common Stock Other Aquire J No No 85.9095 247 21.22K 338,095
30 Jun 21 Korenberg Matthew E Common Stock Other Aquire J No No 85.9095 247 21.22K 39,690
4 Jun 21 Patel Sunil Common Stock Grant Aquire A No No 0 630 0 28,820
4 Jun 21 Patel Sunil NQSO Common Stock Grant Aquire A No No 115.39 3,269 377.21K 3,269

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

91.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 221 235 -6.0%
Opened positions 37 30 +23.3%
Closed positions 51 43 +18.6%
Increased positions 56 79 -29.1%
Reduced positions 101 90 +12.2%
13F shares
Current Prev Q Change
Total value 2.32B 2.26B +2.5%
Total shares 15.24M 22.75M -33.0%
Total puts 596.6K 1.69M -64.8%
Total calls 294.9K 281.6K +4.7%
Total put/call ratio 2.0 6.0 -66.4%
Largest owners
Shares Value Change
BLK Blackrock 2.13M $324.17M +8.2%
Vanguard 1.52M $231.46M +4.1%
William Blair Investment Management 1.29M $196.85M -36.7%
JHG Janus Henderson 1.26M $191.75M -22.0%
STT State Street 782.76K $119.33M -32.8%
Villere ST Denis J & Co 537.03K $81.87M -16.4%
Conestoga Capital Advisors 495.88K $75.6M -30.8%
MCQEF Macquarie 484.36K $73.84M -45.9%
Chicago Capital 448.64K $68.4M +34.8%
Rice Hall James & Associates 430.06K $65.56M -14.7%
Largest transactions
Shares Bought/sold Change
Cardinal Capital Management 0 -1.09M EXIT
Wasatch Advisors 214K -955K -81.7%
William Blair Investment Management 1.29M -749.79K -36.7%
MCQEF Macquarie 484.36K -410.32K -45.9%
STT State Street 782.76K -382.63K -32.8%
JHG Janus Henderson 1.26M -354.57K -22.0%
Eaton Vance Management 5.05K -334.62K -98.5%
Stonepine Capital Management 0 -326.1K EXIT
Conestoga Capital Advisors 495.88K -220.56K -30.8%
Stephens Investment Management 370.81K -211.48K -36.3%

Financial report summary

?
Competition
CytokineticsCurisAbCellera Biologics
Management Discussion
  • Royalty revenue is a function of our partners’ product sales and the applicable royalty rate. Kyprolis royalty rates are under a tiered royalty rate structure with the highest tier being 3.0%. Evomela has a fixed royalty rate of 20%. Contract revenue includes service revenue, license fees and development, regulatory and sales based milestone payments.
  • Royalty revenue increased slightly in Q1 2021 compared to Q1 2020. Captisol sales increased in Q1 2021 compared to Q1 2020, primarily reflecting higher sales of Captisol for use in the manufacturing of remdesivir. Contract revenue increased in Q1 2021 compared to Q1 2020, with the increase primarily attributable to 1) the timing of partner milestone events and 2) the additional contract revenue of $4.2 million and $3.3 million from the acquisitions of Icagen in April 2020 and Pfenex in October 2020, respectively.
  • Total operating costs and expenses increased by $21.1 million, or 72%, primarily due to the acquisition of Pfenex on October 1, 2020 and Icagen on April 1, 2020, as well as increase in Captisol sales revenue for the current period.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: AACR, Abvivo, accelerated, acceleration, adult, affirmative, AI, aldehyde, Aldeyra, allegedly, allergic, alliance, Appeal, appointed, Aptevo, Arcellx, BI, biosimilar, bispecific, breach, breached, Breakthrough, Brian, BTD, carfilzomib, clearance, cohort, consent, construction, construing, consummated, covalent, CPLSA, create, Darzalex, denied, denying, dexamethasone, dismissed, disputed, dosage, downstream, duty, ELAINE, endometrial, engineered, ENKTL, EU, evolution, examine, experienced, expert, extranodal, false, fiduciary, Forsteo, fraudulently, Gertz, GlaxoSmithKline, GSK, hematological, Huntsman, induced, Intelligence, interventional, invasive, INVIGORATE, isatuximab, itching, Jay, joint, lab, lack, landscape, lawsuit, linked, Livogiva, loyalty, Lundstrom, mAb, maximum, medicine, monoclonal, motion, NASDAQ, negotiate, ocular, older, OMT, ophthalmic, oppose, Orphan, PDUFA, Pelican, percentile, powered, prejudice, priority, professor, PTAB, ranked, RASP, reactive, Recombinant, reconciliation, relapsed, relationship, reproxalap, respondent, Sarclisa, score, secondary, shareholder, simulation, slightly, solution, stayed, stop, tearing, temporary, teriparatide, thereof, Thermarex, Toxin, track, Travere, unique, University, unmet, unvested, unwind, urged, User, Utah, violation, withdraw, withheld, workforce
Removed: accept, administration, altogether, amendment, analyze, area, avoid, base, began, borrowing, Branch, California, candidate, care, characterized, charge, Clarifying, collaborator, commencement, comparing, complexity, conduct, confidence, congentia, consistent, contact, counterparty, dependent, depreciable, design, desire, determinable, developed, discovered, disruption, distancing, diversion, document, duration, epidemic, equipment, evolve, excluding, expended, expensed, extend, facility, forced, foreseeable, Francisco, funding, furlough, genetically, globe, good, healthcare, heightening, hospital, hypothetical, identify, Immunovant, implicit, important, imposed, inception, insurance, integrity, Interaction, invention, laboratory, leasehold, located, location, London, maintenance, measuring, monitoring, nonclinical, obligated, OmniRat, oncology, opening, outsourced, pachyonychia, past, people, Pharma, pivotal, preclude, presenting, produce, production, Promacta, promote, prospective, quantifying, receiving, recent, recommended, recruiting, refusal, rent, representing, requirement, residual, restated, restrictive, Retrophin, retrospective, Roivant, San, serving, Simplifying, site, social, South, staffing, Subsequent, supportable, termination, test, tested, title, Topic, transition, transport, travel, variable, Verona, worked